Parvus Therapeutics enters global collaboration and licensing agreement with Genentech to develop Navacim ™ Therapeutics for the treatment of autoimmune diseases

BURLINGAME, Calif. And CALGARY, Alberta – (COMMERCIAL THREAD) – Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory drugs to treat autoimmune diseases without altering normal immunity, has entered into a global collaboration and licensing agreement with group member Genentech Roche, to develop, manufacture and market novel Navacim â„¢ therapeutic products for the treatment of inflammatory bowel disease (IBD), autoimmune liver disease (ALD) and celiac disease (CD). Parvus will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments for each disease area within the collaboration, based on achievement of certain predetermined milestones. Parvus is also eligible to receive certain additional milestone payments in other disease areas, as well as royalties on net sales of products resulting from the collaboration.

“Our collaboration with Genentech is now the second partnership we have entered into with a major biopharmaceutical company, which we believe enhances the potential of our Navacim immunoregulatory therapeutic platform,” said Curtis Ruegg, Ph.D., president and chief executive officer. the direction of Parvus. . “The partnership with Genentech will allow Parvus to expand the Navacim pipeline to treat several debilitating autoimmune diseases in gastroenterology. ”

Under the terms of the agreement, Parvus will conduct preclinical and clinical development activities up to Phase I. Genentech will be responsible for clinical development from Phase II and beyond, including global regulatory submissions and global marketing of products.

“Parvus’ technology represents a potentially transformative approach to the treatment of autoimmune diseases by inducing immune tolerance without causing widespread immune suppression,” said James Sabry, MD, Ph.D., Global Head of Pharma Partnering, Roche . “In preclinical testing, the Parvus platform has shown its ability to induce and develop disease-specific regulatory T cells, which restore balance to the immune system and stop the autoimmune disease process. We look forward to working with the Parvus team to hopefully bring this exciting breakthrough to patients. ”

About Navacims â„¢

Navacims is a precision medicine platform designed to trigger a natural immunoregulatory mechanism in the mammalian immune system that has evolved to protect against autoimmune disease. As selected for each disease, Navacims exhibits a unique peptide-major histocompatibility complex (pMHC) at supra-physiological density, targeting related T cell receptors (TCRs) on disease-relevant T cells. Binding to Navacim causes sustained assembly of TCR microclusters and prolonged signaling leading to differentiation of disease-specific type 1 regulatory T cells (TR1). Since the activity of Navacim depends on the presence of autoimmune T cells causing the disease, their action is self-limited. In preclinical disease models, Navacims has demonstrated broad therapeutic activity and disease reversal in a range of autoimmune disorders, including diabetes, multiple sclerosis, ALD and IBD, while consistently preserving the immunocompetence to resist viral, microbial and tumor challenges.

About Parvus Therapeutics Inc.

Parvus Therapeutics Inc. is a private biopharmaceutical company engaged in the development and commercialization of Navacim therapeutic products targeting autoimmune diseases. The Navacims were discovered by Pere Santamaria, MD, Ph.D. Scientific Director and Founder of Parvus, Julia McFarlane / Professor of Diabetes Canada at the Cumming School of Medicine at the University of Calgary.